Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ROTY Edition 1 Volume 81: We Have A Launch Date!

2018-02-21 seekingalpha
February continues to be our worst month yet, but I focus on positioning the model account for success based on our current plan. (197-0)

ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk

2018-02-16 seekingalpha
I remind readers of our biggest loser to date and why risk management has been key to ROTY`s success. (146-0)

GBT / Global Blood Therapeutics, Inc. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GLOBAL BLOOD THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ☐ Rule 13d-1(b)   ☒ Rule 13d-1(c)   ☐ Rule

GBT / Global Blood Therapeutics, Inc. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GLOBAL BLOOD THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ☐ Rule 13d-1(b)   ☒ Rule 13d-1(c)   ☐ Rule

ROTY Edition 1 Volume 79: Limited Downside Catalysts Vs. Binary Risk

2018-02-14 seekingalpha
We discuss the difference between binary catalysts and those with limited downside, utilizing two recent examples. (166-3)

GBT / Global Blood Therapeutics, Inc. / Third Rock Ventures II, L.P. - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)*     Global Blood Therapeutics, Inc. (Name of Issuer)     COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b)

GBT / Global Blood Therapeutics, Inc. / Third Rock Ventures II, L.P. - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)*     Global Blood Therapeutics, Inc. (Name of Issuer)     COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b)

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following. (313-2)

GBT / Global Blood Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 GLOBAL BLOOD THERAPEUTICS INC COMMON STOCK Cusip #37890U108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37890U108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,337,245 Item 6: 0 Item 7: 5,584,053 Item 8: 0 Item 9: 5,584,053 Item 11: 12.

GBT / Global Blood Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 GLOBAL BLOOD THERAPEUTICS INC COMMON STOCK Cusip #37890U108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37890U108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,337,245 Item 6: 0 Item 7: 5,584,053 Item 8: 0 Item 9: 5,584,053 Item 11: 12.

GBT / Global Blood Therapeutics, Inc. / HENDERSON GROUP PLC - JANUS HENDERSON GROUP OWNS OVER 5% (Passive Investment)

2018-02-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: Global Blood Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 37890U108 Date of Event Which Requires Filing of this Statement: 12/31/2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

GBT / Global Blood Therapeutics, Inc. / HENDERSON GROUP PLC - JANUS HENDERSON GROUP OWNS OVER 5% (Passive Investment)

2018-02-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: Global Blood Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 37890U108 Date of Event Which Requires Filing of this Statement: 12/31/2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

GBT / Global Blood Therapeutics, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
globalbloodtherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Global Blood Therapeutics Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  37890U108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedul

GBT / Global Blood Therapeutics, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
globalbloodtherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Global Blood Therapeutics Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  37890U108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedul


CUSIP: 37890U108